Cannabix Technologies Inc. (CSE: BLO) announced on September 23, 2026, that its BreathLogix™ alcohol screening solution has been deployed at a manufacturing facility in Alabama, marking the company's first delivery of the product to a U.S.-based manufacturing company. The customer is described as a leading industrial printing and manufacturing organisation serving businesses across North America. The deployment is being facilitated through AlcoPro, Inc., an authorised reseller, and signals Cannabix's entry into the U.S. industrial workplace safety market.

Key Points

  • Cannabix Technologies Inc. (CSE: BLO | OTCID: BLOZF | Frankfurt: 8CT)
  • BreathLogix™ deployed at an Alabama manufacturing facility — the first U.S. manufacturing-sector delivery for the product
  • Deployment facilitated by authorised reseller AlcoPro, Inc.; financial terms were not disclosed in the announcement
  • Investors may be watching for additional U.S. commercial deployments across industrial and safety-sensitive sectors

BreathLogix™ System Capabilities and How It Works at the Alabama Site

According to the release, BreathLogix™ screens for alcohol using a breath sample while simultaneously capturing a photograph of the user for identity verification. The system provides Blood Alcohol Content (BAC/BrAC) readings and can automatically deliver alerts via SMS and email to designated managers when positive results are detected. At the Alabama facility, the solution will support routine employee alcohol screening as part of the customer's workplace safety and impairment prevention programme, targeting employees in safety-sensitive work environments.

AlcoPro Partnership Facilitates Cannabix's Entry into U.S. Manufacturing Sector

The Alabama deployment was facilitated by AlcoPro, Inc., identified in the announcement as an authorised reseller of the BreathLogix™ solution. The disclosure suggests that Cannabix is expanding its commercial reach through established distribution relationships rather than direct sales alone. The company did not disclose financial terms, contract value, or the duration of the deployment agreement in the announcement. The customer is described as a leading industrial printing and manufacturing organisation, though the company's name was not disclosed in the release.

Broader U.S. Workplace Safety Market Opportunity Cannabix Is Targeting

The release states that manufacturing facilities, logistics operations, transportation organisations, and other safety-sensitive workplaces are increasingly adopting alcohol screening programmes as part of broader workforce risk management strategies. Cannabix's CEO Rav Mlait noted in the announcement that "employers continue to seek practical tools that can help reduce impairment-related risks, improve workplace safety, and support compliance with corporate safety policies." The company positions BreathLogix™ as applicable across a wide range of screening scenarios, including contractor screening, return-to-work assessments, and random testing programmes.

Cannabix Technologies' Broader Product Portfolio and Market Context

Beyond BreathLogix™, Cannabix Technologies also develops the Marijuana Breath Test (MBT), which targets delta-9 THC in breath to identify recent cannabis use. The company is headquartered in Burnaby, British Columbia. The immediate share price impact of the Alabama deployment announcement was not clear from available public information. Investors may be watching how successfully the company converts this initial U.S. manufacturing deployment into additional commercial agreements.